Confirming a pretty active recent rumor mill in the generic and specialty drug space, Actavis (NYSE:ACT) announced on Monday that it had reached an agreement to acquire Warner Chilcott (Nasdaq:WCRX)
in an all-stock deal. This deal should bring real long-term value for
Actavis, while giving the owners of long-struggling Warner Chilcott an
honorable exit.
The Deal To Be
Assuming that the deal gets the request approvals and a rival suitor
doesn't break things up, Actavis will acquire Warner Chilcott in an $8.5
billion all-stock deal that values Warner Chilcott at $20.08 a share – a
roughly 5% premium to Friday's close, but closer to a 50% premium
relative to where the shares were trading before spiking on M&A rumors.
Please read the full article here:
http://www.investopedia.com/stock-analysis/052113/good-deal-actavis-warner-chilcott-goes-little-cheap-act-wcrx-vrx-myl.aspx
No comments:
Post a Comment